As a new wave of type 2 diabetes and obesity drugs takes the industry by storm,
Glyscend Therapeutics
has tapped a new CEO to lead the charge for its candidate designed to mimic metabolic surgery.
Sapan Shah
is taking the driver’s seat at Glyscend as founding CEO
Ashish Nimgaonkar
shifts to other roles as chief medical officer and head of R&D, the company
announced
on Tuesday. The news comes just a few months after Glyscend
unveiled topline data
from a Phase IIa suggesting its lead candidate,
GLY-200
, helped type 2 diabetes patients achieve significant reductions in blood glucose and a decrease in body weight. The company hopes the oral drug will have the same effects as metabolic surgery without the cost and complications from the invasive procedure.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.